Baird Medical Investment Holdings Limited (BDMD) stock analysis

Healthcare · Medical Devices

From the 20-F/A filed 2026-07-27

How it makes money

Hospitals buy microwave ablation devices through its network of distributors and deliverers.

Hospitals pay for devices because they need to treat thyroid issues. The use of deliverers drives results by allowing the company to reach a large group of hospitals at once, reducing time and costs.

By leveraging established channels through distributors and deliverers, the company can scale its market presence more efficiently than through direct sales alone.

What protects it: the moat

It claims market leadership in the PRC for microwave ablation needle sales in 2022.

The company claims it has a competitive advantage through a specialized focus on thyroid health and a full-stack technology strategy.

It cites a report stating it was the top provider of microwave ablation needles in the PRC in 2022 based on both sales revenue and volume.

What growth costs

It reinvests in research, development, and regulatory certifications.

The company reinvests in its product pipeline through research and development.

These costs include expenditures on AI-integrated robotic systems and fees for regulatory milestones, such as FDA certification and CE Marking. For the year ended December 31, 2025, research and development service fees contributed to a net loss of US$27.5 million.

What could damage it

Administrative oversight in renewing manufacturing licenses can trigger cash freezes.

Administrative errors can lead to regulatory issues.

Specifically, failing to renew a manufacturing license can result in penalties and a freeze on cash, which limits the funds available for the company's operating needs.

About Baird Medical Investment Holdings Limited

Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.

Other companies in Medical Devices